Tue, February 21, 2023
[ 12:00 AM ] - WOPRAI
Wed, February 8, 2023
Thu, January 19, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Wed, January 11, 2023
[ 12:00 AM ] - WOPRAI
Mon, December 12, 2022
[ 12:00 AM ] - WOPRAI
Fri, October 14, 2022
[ 12:00 AM ] - WOPRAI
Wed, August 17, 2022
[ 12:00 AM ] - WOPRAI
Tue, July 26, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Fri, July 15, 2022
[ 12:00 AM ] - WOPRAI
Thu, June 23, 2022
[ 12:00 AM ] - WOPRAI
Tue, May 17, 2022
[ 12:00 AM ] - WOPRAI
Wed, May 11, 2022
[ 12:00 AM ] - WOPRAI
Fri, May 6, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Fri, April 22, 2022
[ 12:00 AM ] - WOPRAI
Thu, March 31, 2022
Fri, November 19, 2021
[ 12:00 AM ] - WOPRAI
Tue, February 2, 2021
[ 12:00 AM ] - WOPRAI
Mon, January 25, 2021
Tue, January 5, 2021
Fri, December 18, 2020
Thu, May 7, 2020
[ 12:00 AM ] - WOPRAI
Thu, April 30, 2020
[ 12:00 AM ] - WOPRAI
Mon, November 25, 2019
Do Kim Maintained (TVTX) at Buy with Increased Target to $46 on, Feb 21st, 2023
Do Kim of Piper Sandler, Maintained "Travere Therapeutics, Inc." (TVTX) at Buy with Increased Target from $42 to $46 on, Feb 21st, 2023.
Do has made no other calls on TVTX in the last 4 months.
There are 2 other peers that have a rating on TVTX. Out of the 2 peers that are also analyzing TVTX, 1 agrees with Do's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Alex Thompson of "Stifel" Initiated at Hold and Held Target at $22 on, Wednesday, December 14th, 2022
This is the rating of the analyst that currently disagrees with Do
- Edward Nash of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $40 on, Monday, January 30th, 2023
Contributing Sources